NEW YORK (GenomeWeb) – Skyline Medical announced today that it will collaborate with Helomics to develop new personalized cancer diagnostics using the Helomics D-Chip platform.
Helomics has collected large quantities of data on patients with cancer through its ChemoFx precision cancer diagnostic. The repository contains drug response information for more than 149,000 patient tumors, as well as their molecular, genomic, biochemical, and histopathology data coupled to de-identified patient demographics.
The D-Chip platform uses artificial intelligence-powered bioinformatics to find insights from the data to help disease diagnosis, produce new diagnostics and therapies, perform improved clinical trials, and help inform programs that seek to find new purposes for existing medications.
“The insights gained from this research… are helping to inform the next phase of development of our D-Chip platform, which will associate whole genome data with Helomics tumor profile and drug sensitivity data,” Helomics CEO and President Gerald Vardzel said in a statement.
Specific terms of the collaboration were not disclosed.